Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? DOI Creative Commons
Miodrag Janić, Sabina Škrgat, Matevž Harlander

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2030 - 2030

Published: Dec. 9, 2024

Chronic respiratory disorders are the third leading cause of mortality globally. Consequently, there is a continuous pursuit effective therapies beyond those currently available. The therapeutic potential glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide/GLP-1 (GIP/GLP-1) receptor agonists extends regulation glycemia, including glucometabolic, cardiovascular, renal effects, rendering them viable candidates, due to their mechanisms action, for possible treatment disorders. This manuscript aims provide comprehensive evaluation evidence on direct (cellular) indirect (metabolic) actions GLP-1 GIP/GLP-1 within pulmonary systems. In addition, it examines efficacy in addressing prevalent disorders, specifically chronic obstructive disease (COPD), asthma, pneumonia, sleep apnea, hypertension, lung cancer, transplantation. Finally, seeks identify avenues further focused research this field.

Language: Английский

The interactions among factors associated with the risk of lung cancer among diabetes patients: a survival tree analysis DOI Creative Commons

Sarah Tsz Yui Yau,

C.T. Hung, Eman Leung

et al.

npj Primary Care Respiratory Medicine, Journal Year: 2025, Volume and Issue: 35(1)

Published: March 30, 2025

Abstract Past epidemiological studies demonstrated mixed findings on the association between diabetes and lung cancer. Given possible links diabetes, smoking, respiratory diseases, this study aims to examine interaction patterns among factors associated with risk of cancer patients. A territory-wide retrospective cohort was performed using electronic health records Hong Kong. Patients who received care in general outpatient clinics 2010 2019 without history were included followed up until December 2019. Conditional inference survival tree applied total 385,521 patients included. During a median follow-up 6.2 years, 3395 developed Age emerged as primary factor differentiating age ( ≤ 64 vs >64 years), smoking appeared subsequent dominant within each subpopulation. Among old smokers aged years characterized by long duration (median: 6–8 chronic obstructive pulmonary disease (COPD) key factor. Six distinct subgroups different levels according age, metformin use, COPD status identified. Findings suggest patients, providing targets for public interventions.

Language: Английский

Citations

0
Disease burden of cancers attributable to high fasting plasma glucose from 1990 to 2021 and projections until 2031 in China DOI
Zhong Zheng, Shaojie Xu, Jicun Zhu

et al.

Cancer Epidemiology, Journal Year: 2024, Volume and Issue: 94, P. 102725 - 102725

Published: Dec. 20, 2024

Language: Английский

Citations

1
Highlights of the Current Issue DOI Creative Commons
Ningjian Wang, Anoop Misra

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2024, Volume and Issue: 18(2), P. 102985 - 102985

Published: Feb. 1, 2024

Language: Английский

Citations

0
Mendelian randomization study of the relationship between blood and urine biomarkers and lung cancer DOI Creative Commons
Haihua Huang,

Zheng Haijun

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 2, 2024

Identifying suitable biomarkers is crucial for exploring the pathogenesis, early screening, and therapeutic monitoring of lung cancer. This study aims to analyze comprehensively associations between cancer in blood urine.

Language: Английский

Citations

0
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? DOI Creative Commons
Miodrag Janić, Sabina Škrgat, Matevž Harlander

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2030 - 2030

Published: Dec. 9, 2024

Chronic respiratory disorders are the third leading cause of mortality globally. Consequently, there is a continuous pursuit effective therapies beyond those currently available. The therapeutic potential glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide/GLP-1 (GIP/GLP-1) receptor agonists extends regulation glycemia, including glucometabolic, cardiovascular, renal effects, rendering them viable candidates, due to their mechanisms action, for possible treatment disorders. This manuscript aims provide comprehensive evaluation evidence on direct (cellular) indirect (metabolic) actions GLP-1 GIP/GLP-1 within pulmonary systems. In addition, it examines efficacy in addressing prevalent disorders, specifically chronic obstructive disease (COPD), asthma, pneumonia, sleep apnea, hypertension, lung cancer, transplantation. Finally, seeks identify avenues further focused research this field.

Language: Английский

Citations

0